
The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.
View the Pharmaceutical Executive May 2025 issue in an interactive format.
over 1 year ago
Your Voice Boxover 1 year ago
Pharm Exec's 2025 State of the Industry Surveyover 1 year ago
Reshema Kemps-Polanco: Taking Risks for Greater Rewardover 1 year ago
Earned Media and ASCO: Provide Context Beyond the Dataover 1 year ago
How Does the Shift to Early-Stage M&A Change Due Diligence?over 1 year ago
The Three Pillars of Pharma’s New Commercial Modelover 1 year ago
Revenue Optimization: The Money Matters—That Matter Mostover 1 year ago
Bridging the Gap: A Large Pharma Blueprint





